Propensity score-matched comparison of vaccine in patients with cancer with and without vaccination (N=127 pairs)
| Vaccinated | Non-vaccinated | P value | ||
| Age, mean (SD) | ||||
| Gender, no (%) | Male | 28 (22.0) | 33 (26.0) | 0.46 |
| Female | 99 (78.0) | 94 (74.0) | ||
| PD-1B treatment duration duration, weeks | 6.54±2.33 | 6.56±2.30 | 0.96 | |
| ECOG-PS | 0 | 85 (66.9%) | 89 (70.1%) | 0.59 |
| 1 | 42 (33.1%) | 38 (29.9%) | ||
| Metastases | Yes | 10 (7.9%) | 10 (7.9%) | 1 |
| No | 117 (92.1%) | 117 (92.1%) | ||
| Chemotherapy | Yes | 26 (20.5%) | 30 (23.6%) | 0.55 |
| No | 101 (79.5%) | 97 (76.4%) | ||
| Comorbid rheumatic disease | Yes | 28 (22.0%) | 26 (20.5%) | 0.76 |
| No | 99 (78.0%) | 101 (79.5%) | ||
| Pathology | NSCLC | 42 (33.1%) | 46 (36.2%) | 0.59 |
| GI | 59 (46.4%) | 51 (40.2%) | ||
| HN | 26 (20.5%) | 30 (23.6%) | ||
| Diarrhea | Yes | 9 (7.1%) | 11 (8.7%) | 0.64 |
| No | 118 (92.9%) | 116 (91.3%) | ||
| Pneumonitis | Yes | 7 (5.5%) | 8 (6.3%) | 0.79 |
| No | 120 (94.5%) | 119 (93.7%) | ||
| Rash | Yes | 30 (23.6%) | 29 (22.8%) | 0.88 |
| No | 97 (76.4%) | 98 (76.2%) | ||
| Arthralgia | Yes | 17 (13.4%) | 18 (14.2%) | 0.86 |
| No | 110 (86.6%) | 109 (85.8%) | ||
| Liver function test | Yes | 16 (12.6%) | 15 (11.8%) | 0.85 |
| No | 111 (87.4%) | 112 (88.2%) | ||
ECOG-PS, Eastern Cooperative Oncology Group-Performance Score; GI, gastrointestinal; HN, head and neck; PD-1B, progression cell death-1 blockers.